Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome)

Clinical Rheumatology

Volumn 25, Issue 6, 2006, Pages 782-788

  Calguneri, Meral ^a   Ozbalkan, Zeynep ^a,c   Ozturk, M Akif ^b   Apras, Sule ^a   Ertenli, A Ihsan ^a   Kiraz, Sedat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c NONE   (Turkey)

Author keywords

Complications; Corticosteroids; Cyclophosphamide; Lupus nephritis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHLOROQUINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; MESNA; METHYLPREDNISOLONE; ONDANSETRON; PREDNISOLONE; PROTON PUMP INHIBITOR; STEROID;

ADULT; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG PULSE THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LEIOMYOSARCOMA; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MORTALITY; NAUSEA AND VOMITING; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS INFECTION;

ADMINISTRATION, ORAL; ADULT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; GLUCOCORTICOIDS; HEMATURIA; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LEUKOPENIA; LONGITUDINAL STUDIES; LUPUS NEPHRITIS; MALE; MENSTRUATION DISTURBANCES; METHYLPREDNISOLONE; MIDDLE AGED; OBESITY; TREATMENT OUTCOME;

EID: 33746898509     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0217-2     Document Type: Review

References (31)

1. Donadio JV, Hart GM, Bergstralh EJ, Holley KE (1995) Prognostic determinants in lupus nephritis: A long term clinicopathological study. Lupus 4:109-115
2. Ward MM, Pyun E, Studenski S (1996) Mortality risk associated with specific clinical manifestations of systemic lupus erythematosus. Arch Intern Med 156:1337-1344
3. Vu TV, Escalante A (1999) A comparison of the quality of life of patients with systemic lupus erythematosus with and without end-stage renal disease. J Rheumatol 26:2595-2601
4. Mok CC, Wong RWS, Lau CS (1999) Lupus nephritis in southern Chinese patients: Clinicopathological findings and long-term outcome. Am J Kidney Dis 34:315-323
5. Appel GB, Valeri A (1994) The course and treatment of lupus nephritis. Annu Rev Med 45:525-537
6. Bakir AA, Levy PS, Dunea G (1994) The prognosis of lupus nephritis in African-Americans: A retrospective analysis. Am J Kidney Dis 24:159-171
7. Austin HA III, Klippel JH, Balow JE, le Riche NGH, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis: Controlled trial of prednisone and cyctotoxic drugs. N Engl J Med 314:614-619
8. Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those threaded with prednisone only. Arthritis Rheum 34:945-950
9. Boumpas DT, Austin HA III, Voughan EM, Klippel JH, Steinberg AD, Yarboro CH et al (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-751
10. Gourley MF, Austin HA III, Scott D, Yarboro CH, Voughan EM, Muir J et al (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 125:549-557
11. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH et al (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135:248-257
12. Pisoni CN, Karim Y, Cuadrado MJ (2005) Mycophenolate mofetil and systemic lupus erythematosus: An overview. Lupus 14(Suppl 1):9-11
13. Thatayatikom A, White AJ (2006) Rituximab: A promising therapy in systemic lupus erythematosus. Autoimmun Rev 5:18-24
14. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366-369
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1991) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 34:945-950
16. Gordon C (2003) Assessing disease activity and out come in systemic lupus erythematosus. In: Hochberg MC, Silman A, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology. Mosby, Edinburgh, pp 1389-1393
17. Boumpas DT, Balow JE (1998) Outcome criteria for lupus nephritis trials: a critical overview. Lupus 7:622-629
18. Austin HA, Balow JE (1999) Natural history and treatment of lupus nephritis. Semin Nephrol 19:2-11
19. Ortmann RA, Klippel JH (2000) Update on cyclophosphamide for systemic lupus erythematosus. Rheum Dis Clin North Am 26:363-375
20. D'Cruz D, Cuadrado MJ, Mujic F et al (1997) Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 15:275-282
21. Houssiau FA, Vasconcelos C, D'cruz D, Sebastiani GD, Garrido ER, Danieli MG, Abramovicz D et al (2002) Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121-2131
22. Martin-Suarez I, D'Cruz D, Mansoor M et al (1997) Immunosuppressive treatment in severe connective tissue diseases: Effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 56:481-487
23. Mok CC, Kwan Ho CT, Siu YP, Chan KW, Kwan TH et al (2001) Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 38:256-264
24. Chan TM, Li FK, Wong RW et al (1995) Sequential therapy for diffuse proliferative and membranous lupus nephritis: Cyclophosphamide and prednisolone followed by azathioprine and prednisolone. Nephron 71:321-327
25. Golbus J, Mc Cune WJ (1994) Lupus nephritis. Classification, prognosis, immunopathogenesis and treatment. Rheum Dis Clin North Am 20:213-242
26. Gladman DD, Krowitz MD (2000) Clinical features of SLE. Klippel Dieppe Sec. Edd. Mosby, London, pp 7.1.5-7.1.8
27. Contreras G, Pardo V, Leclercq B, Lenzo O, Tozman E, O'Nas P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350:971-980
28. Klinlen LJ (1985) Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78(Suppl 1A):44-49
29. Fox DA, McCune J (1994) Immunosuppressive therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 20:265-299
30. Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheum 39:1050-1054
31. Belmont HM, Storch M, Buyon J, Abramson S (1995) New York University/ Hospital for joint disease experience with intravenous cyclophosphamide treatment: Efficacy in steroid unresponsive lupus nephritis. Lupus 4:104-108